MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caballero, R.
Right arrow Articles by Tamargo, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caballero, R.
Right arrow Articles by Tamargo, J.

Vol. 59, Issue 4, 825-836, April 2001

Direct Effects of Candesartan and Eprosartan on Human Cloned Potassium Channels Involved in Cardiac Repolarization

Ricardo Caballero, Eva Delpón, Carmen Valenzuela, Mónica Longobardo, Teresa González, and Juan Tamargo

Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain

In the present study, we analyzed the effects of two angiotensin II type 1 receptor antagonists, candesartan (0.1 µM) and eprosartan (1 µM), on hKv1.5, HERG, KvLQT1+minK, and Kv4.3 channels expressed on Ltk- or Chinese hamster ovary cells using the patch-clamp technique. Candesartan and eprosartan produced a voltage-dependent block of hKv1.5 channels decreasing the current at +60 mV by 20.9 ± 2.3% and 14.3 ± 1.5%, respectively. The blockade was frequency-dependent, suggesting an open-channel interaction. Eprosartan inhibited the tail amplitude of HERG currents elicited on repolarization after pulses to +60 mV from 239 ± 78 to 179 ± 72 pA. Candesartan shifted the activation curve of HERG channels in the hyperpolarizing direction, thus increasing the current amplitude elicited by depolarizations to potentials between -50 and 0 mV. Candesartan reduced the KvLQT1+minK currents elicited by 2-s pulses to +60 mV (38.7 ± 6.3%). In contrast, eprosartan transiently increased (8.8 ± 2.7%) and thereafter reduced the KvLQT1+minK current amplitude by 17.7 ± 3.0%. Eprosartan, but not candesartan, blocked Kv4.3 channels in a voltage-dependent manner (22.2 ± 3.5% at +50 mV) without modifying the voltage-dependence of Kv4.3 channel inactivation. Candesartan slightly prolonged the action potential duration recorded in guinea pig papillary muscles at all driving rates. Eprosartan prolonged the action potential duration in muscles driven at 0.1 to 1 Hz, but it shortened this parameter at faster rates (2-3 Hz). All these results demonstrated that candesartan and eprosartan exert direct effects on Kv1.5, HERG, KvLQT1+minK, and Kv4.3 currents involved in human cardiac repolarization.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 EuropaceHome page
A. Bollmann, A. Tveit, D. Husser, M. Stridh, L. Sornmo, P. Smith, and S. B. Olsson
Fibrillatory rate response to candesartan in persistent atrial fibrillation
Europace, October 1, 2008; 10(10): 1138 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. Walcher, K. Hess, P. Heinz, K. Petscher, D. Vasic, U. Kintscher, M. Clemenz, M. Hartge, K. Raps, V. Hombach, et al.
Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-{gamma}
Hypertension, February 1, 2008; 51(2): 259 - 266.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J. R. Ehrlich, S. H. Hohnloser, and S. Nattel
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence
Eur. Heart J., March 1, 2006; 27(5): 512 - 518.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
S. G. Williams, D. T. Connelly, M. Jackson, A. Bennett, K. Albouaini, and D. M. Todd
Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?
Europace, January 1, 2005; 7(6): 554 - 559.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Caballero, R. Gomez, L. Nunez, I. Moreno, J. Tamargo, and E. Delpon
Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations
Cardiovasc Res, December 1, 2004; 64(3): 457 - 466.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon
Pharmacology of cardiac potassium channels
Cardiovasc Res, April 1, 2004; 62(1): 9 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Caballero, R. Gomez, I. Moreno, L. Nunez, T. Gonzalez, C. Arias, M. Guizy, C. Valenzuela, J. Tamargo, and E. Delpon
Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current
Cardiovasc Res, April 1, 2004; 62(1): 86 - 95.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
I. Moreno, R. Caballero, T. Gonzalez, C. Arias, C. Valenzuela, I. Iriepa, E. Galvez, J. Tamargo, and E. Delpon
Effects of Irbesartan on Cloned Potassium Channels Involved in Human Cardiac Repolarization
J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 862 - 873.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Caballero, I. Moreno, T. Gonzalez, C. Valenzuela, J. Tamargo, and E. Delpon
Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5)
Cardiovasc Res, October 1, 2002; 56(1): 104 - 117.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics